France Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The France Continuous Glucose Monitoring (CGM) market is forecast to experience substantial growth, reaching USD 0.33 billion in 2031 from USD 0.11 billion in 2026. This expansion represents a robust Compound Annual Growth Rate (CAGR) of 24.6% over the forecast period, indicating a rapidly developing market.

The France Continuous Glucose Monitoring market is segmented by application and end-user. This categorization provides critical insights into the specific uses of CGM devices and the types of consumers or healthcare settings driving demand, allowing for a detailed understanding of market dynamics within the country.

The demand for CGM devices in France is primarily driven by the high prevalence of type 1 and type 2 diabetes, affecting 8.6% of French adults in 2021. Additionally, continuous product launches by key market players, rising government initiatives to educate on diabetic health, decreasing device costs, and increasing CGM reimbursement policies are significant contributors to market growth.

A critical demographic trend impacting the French CGM market is the growing incidence of diabetes, with the number of affected adults projected to increase from 3.9 million in 2021 to 4.2 million by 2045. Furthermore, 4.8 million people have impaired glucose tolerance, which is expected to reach 4.9 million by 2045, creating a sustained and increasing demand for glucose monitoring solutions.

Continuous product launches by key market players are a major impetus, driving innovation and expanding product availability. Concurrently, various government policies, programs, and services aimed at diabetes management, alongside increasing CGM reimbursement, are actively spurring market growth by enhancing accessibility and affordability for patients in France.

CGM devices are essential for diabetic patients in France because they provide continuous tracking of blood sugar levels, which is crucial for making timely insulin adjustments and preventing severe complications like hypoglycemia. Given that 8.6% of French adults have diabetes and it's a leading cause of death, CGM devices are vital for improving patient quality of life and managing the associated health risks.